drugset / Trial / NCT00473694

Comparison of Sugammadex (MK-8616/Org 25969) With Neostigmine Administered at 1-2 Post-tetanic Counts (PTCs) After Administration of Rocuronium or Vecuronium (19.4.302/P05945/MK-8616-025)

NCT00473694

Phase 3 Completed 182 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of the trial is to demonstrate a faster recovery from neuromuscular block (NMB) induced with rocuronium or vecuronium after reversal by 4.0 mg/kg of Org 25969 compared with reversal by 70 μg/kg of neostigmine in combination with 14 μg/kg glycopyrrolate.

Timeline

Start
2005-11-28
Primary completion
2006-11-06
Completion
2007-01-29

Drugs

EvaluationDrugModalityDoseRoute
Comparator Neostigmine Other / unclassified 70 ug/kg Intravenous
Subject Sugammadex Other / unclassified 4 mg/kg Intravenous
Comparator Glycopyrrolate Small molecule 14 ug/kg Intravenous
Background Rocuronium Other / unclassified 0.15 mg/kg Intravenous
Background Vecuronium Small molecule 0.015 mg/kg Intravenous

Indications

No indication recorded.